{
    "id": 23431,
    "fullName": "ERBB2 E717K",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ERBB2 (HER2) E717K lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). E717K has been demonstrated to confer resistance to Tykerb (lapatinib) in cell culture (PMID: 18413839), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 5983,
                    "pubMedId": 18413839,
                    "title": "EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18413839"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "E717K",
    "createDate": "06/21/2016",
    "updateDate": "10/21/2019",
    "referenceTranscriptCoordinates": {
        "id": 170467,
        "transcript": "NM_004448",
        "gDna": "chr17:g.39723601G>A",
        "cDna": "c.2149G>A",
        "protein": "p.E717K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7310,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing ERBB2 (HER2) E717K demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).",
            "molecularProfile": {
                "id": 24119,
                "profileName": "ERBB2 E717K"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5983,
                    "pubMedId": 18413839,
                    "title": "EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18413839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7316,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E717K in culture (PMID: 18413839).",
            "molecularProfile": {
                "id": 24119,
                "profileName": "ERBB2 E717K"
            },
            "therapy": {
                "id": 967,
                "therapyName": "XL647",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5983,
                    "pubMedId": 18413839,
                    "title": "EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18413839"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24119,
            "profileName": "ERBB2 E717K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 170468,
            "transcript": "NM_001289937",
            "gDna": "chr17:g.39723601G>A",
            "cDna": "c.2149G>A",
            "protein": "p.E717K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 170467,
            "transcript": "NM_004448",
            "gDna": "chr17:g.39723601G>A",
            "cDna": "c.2149G>A",
            "protein": "p.E717K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}